Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.04 USD
+0.83 (1.01%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $83.05 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.04 USD
+0.83 (1.01%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $83.05 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
The Tech Sector's Strong Earnings Power
by Sheraz Mian
Technology sector's Q1 results are coming from a diverse cross-section of companies.
BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017
What to Expect from Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.
What's in Store for Merck (MRK) this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
by Zacks Equity Research
Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
by Arpita Dutt
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.
Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.
Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback
by Arpita Dutt
Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.
Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.
KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Gilead Sciences (GILD)
by Kevin Cook
Could a transformational M&A deal reverse the 18-month slide in sales and profits?
Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
by Arpita Dutt
Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.
Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Galapagos Initiates 3 Phase II Studies for Filgotinib
by Zacks Equity Research
Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.
New Strong Sell Stocks for March 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: